Prothena Corp Public (PRTA) Research & Development (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly Research & Development of $12.6 million for Q1 2026, down 75.15% year-over-year from $50.8 million in Q1 2025, and down 13.43% quarter-over-quarter from $14.6 million in Q4 2025.
Prothena Corp Public (PRTA) Research & Development (2012 - 2026) Analysis & Trends
Prothena Corp Public's Research & Development history runs 15 years deep, the most recent figure standing at $12.6 million for Q1 2026.
- In Q1 2026, Research & Development fell 75.15% year-over-year to $12.6 million; the TTM figure through Mar 2026 stood at $96.7 million (down 53.8% YoY), while the FY2025 annual figure was $134.9 million, down 39.4% from the prior year.
- Research & Development for Q1 2026 stood at $12.6 million, down from $14.6 million in the prior quarter.
- The five-year high for Research & Development was $64.1 million in Q1 2024, with the low at $12.6 million in Q1 2026.
- The 5-year median for Research & Development is $44.8 million (2023), against an average of $42.7 million.
- The sharpest annual moves came in 2022 and 2026: Research & Development jumped 121.54% in 2022, then slumped 75.15% in 2026.
- Prothena Corp Public's Research & Development stood at $36.9 million in 2022, then jumped by 67.86% to $61.9 million in 2023, then slipped by 18.93% to $50.2 million in 2024, then slumped by 70.93% to $14.6 million in 2025, then slipped by 13.43% to $12.6 million in 2026.
- Business Quant data shows PRTA's Research & Development at $12.6 million in Q1 2026, $14.6 million in Q4 2025, and $28.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - | 8.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.80 Mn |
| Mar 31, 2026 | 12.63 Mn |
| Dec 31, 2025 | 14.59 Mn |
| Sep 30, 2025 | 28.94 Mn |
| Jun 30, 2025 | 40.52 Mn |
| Mar 31, 2025 | 50.81 Mn |
| Dec 31, 2024 | 50.17 Mn |
| Sep 30, 2024 | 50.72 Mn |
| Jun 30, 2024 | 57.51 Mn |
| Mar 31, 2024 | 64.11 Mn |
| Dec 31, 2023 | 61.89 Mn |
| Sep 30, 2023 | 57.91 Mn |
| Jun 30, 2023 | 56.01 Mn |
| Mar 31, 2023 | 44.76 Mn |
| Dec 31, 2022 | 36.87 Mn |
| Sep 30, 2022 | 39.86 Mn |
| Jun 30, 2022 | 31.57 Mn |
| Mar 31, 2022 | 27.26 Mn |
| Dec 31, 2021 | 22.06 Mn |
| Sep 30, 2021 | 17.99 Mn |